VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

August 31, 2014

Conditions
Macular Degeneration
Interventions
BIOLOGICAL

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.

DRUG

Visudyne

Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.

Trial Locations (14)

100044

Beijing

100083

Beijing

100730

Beijing

300384

Tianjin

310003

Hangzhou

310009

Hangzhou

410011

Changsha

510060

Guangzhou

610041

Chengdu

710032

Xi'an

2000080

Beijing

Unknown

Qingdao

Wenzhou

Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY